{
    "nctId": "NCT00206453",
    "briefTitle": "Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer",
    "officialTitle": "An Extension Phase II Study of the Clinical and Biologic Effects of Docetaxel (Taxotere) in Patients With Locally Advanced Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 25,
    "primaryOutcomeMeasure": "biologic effects of Taxotere",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. All patients must be female\n2. Locally advanced breast cancers or primary breast cancers with concomitant gross metastatic disease are eligible; locally advanced cancers must be of clinical and/or radiologic size \\> 4 cm and/or are deemed surgically inoperable.\n3. Negative serum pregnancy test (beta-human chorionic gonadotropin \\[b-HCG\\]) within 7 days of starting study, if of childbearing potential\n4. Kidney and liver function tests - all within 1.5 times of the institution's upper limit of normal\n5. Performance status (World Health Organization \\[WHO\\] scale) \\< 2 and life expectancy \\> 6 months\n6. Age \\> 18 years old\n7. No brain and/or leptomeningeal disease\n8. No previous or current malignancies at other sites within the last 5 years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.\n\nExclusion Criteria:\n\n1. Pregnancy or unwillingness to use a reliable contraceptive method in women of child-bearing potential.\n2. Severe underlying chronic illness or disease\n3. Patients on other investigational drugs while on study will be excluded.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}